Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 5

Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors

Klinik olarak aşikar kardiyovasküler hastalığı ya da geleneksel ateroskleroz risk faktörü bulunmayan psöriatik artritli hastalarda subklinik aterosklerozun değerlendirilmesi

Pages
358–365
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Inall, 23 (76.7%) of the PsA patients and 5 (16.7%) of the RApatients were using an anti-tumor necrosis factor alpha therapy (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cardiovascular disease (CVD) is more prevalentin almost all patients with chronic inflammatory musculoskeletal diseases than in their healthy counterparts.
📊
Key Findings & Data:The aim of thisstudy was to assess the presence of subclinical atherosclerosisin patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthritis (RA) and healthy controls.Methods: A total of 30 patients with PsA, 30 patients with RA,and 30 healthy controls were enrolled in this parallel groupstudy.
💡
Conclusion & Impact:Inall, 23 (76.7%) of the PsA patients and 5 (16.7%) of the RApatients were using an anti-tumor necrosis factor alpha therapy (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Cardiovascular disease (CVD) is more prevalentin almost all patients with chronic inflammatory musculoskeletal diseases than in their healthy counterparts. The aim of thisstudy was to assess the presence of subclinical atherosclerosisin patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthritis (RA) and healthy controls.Methods: A total of 30 patients with PsA, 30 patients with RA,and 30 healthy controls were enrolled in this parallel groupstudy. Demographic, clinical, and laboratory data of the groupswere recorded. The Disease Activity Score-28 tool was usedfor joint assessment. The erythrocyte sedimentation rate andC-reactive protein level were measured as acute phase reactants. Flow-mediated dilatation (FMD) and carotid intima mediathickness (CIMT) were also measured in all participants.Results: The median duration of disease in patients withPsA was 60 months (range: 8–216 months). A total of 22 of30 (73.3%) PsA patients had a diagnosis of psoriasis and13 (48.1%) had active disease. The study groups were similar with regard to age, gender, and body mass index data. Inall, 23 (76.7%) of the PsA patients and 5 (16.7%) of the RApatients were using an anti-tumor necrosis factor alpha therapy (p

Özet

Amaç: Kardiyovasküler hastalıklar kronik enflamatuvar kasiskelet hastalığı olan hastaların hemen hepsinde sağlıklı akranlarına göre daha sıktır. Bu çalışmada psöriatik artritli (PsA) hastalarda subklinik ateroskleroz varlığı hem romatoid artrit (RA) hem de sağlıklı kontrol bireyleri ile karşılaştırılarak değerlendirilmiştir. Yöntemler: Paralel grup çalışmamıza PsA bulunan 30 hasta, RA bulunan 30 hasta ve 30 sağlıklı kontrol bireyi alındı. Katılımcıların tüm demografik, klinik ve laboratuvar verileri kaydedildi. Eklem aktivitesi hastalık aktivite skoru (DAS)-28 ile değerlendirildi. Eritrosit sedimentasyon hısı (ESH) ve C-reaktif protein (CRP) düzeyleri akut faz reaktanı olarak ölçüldü. Tüm katılımcılarda akım aracılı dilatasyon (AAD) ve karotis intima mediya kalınlığı (KİMK) ölçüldü. Bulgular: Psöriatik artritli hastalardaki ortanca hastalık süresi 60 (dağılım, 8–216) aydı. 22/30 (%73.3) PsA’lı hastalarda psöriasis tanısı daha önce konmuştu ve bunların 13/30’unda (%48.1) hastalık aktifti. Çalışma grupları yaş, cinsiyet ve vücut kitle indeksi açısından benzerdi. Yirmi üç (%76.7) PsA’lı hasta ve RA’lı beş (%16.7) hastaya anti-tümör nekrozis faktör (TNF)- alfa tedavisi uygulanıyordu (p

🔖

Cite This Article

Kalyoncu, U., Kiraz, S., Karadağ, Ö., Kılıç, L., Ertenli, İ., Erden, A., Aytemir, K., Akdoğan, A., Canpolat, U., Bilgen, Ş. A. (2022). Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 5, 358–365. https://ajindex.com/articles/632197

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73. [CrossRef] 2. Di Minno MN, Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med 2015;47:346–53. [CrossRef] 3. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012;38:497–505. [CrossRef] 4. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131–5. [CrossRef] 5. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868–72. [CrossRef] 6. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211–6. [CrossRef] 7. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63. 8. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al; Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233–46. [CrossRef] 9. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011;10:773–8. [CrossRef] 10. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322–31. [CrossRef] 11. Yilmazer B, Sahin T, Unlu BÖ, Kir HM, Cefle A. Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 2015;35:1385– 92. [CrossRef] 12. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al; Working Gro